Medicus Pharma Acquires Antev, Sees $6 Billion Market Potential

Medicus Pharma has completed its acquisition of Antev Limited, a UK-based drug development company, for $2.97 million in cash and 1.6 million common shares. The acquisition adds strategic depth to Medicus' drug development pipeline and strengthens its team. The company believes Teverelix, a next-generation GnRH antagonist, has a potential market opportunity of $6 billion for preventing acute urinary retention relapse due to enlarged prostate and treating advanced prostate cancer in high-risk patients.

Medicus Pharma Ltd. (NASDAQ: MDCX), a biotech/life sciences company focused on advancing the clinical development of novel therapeutics, has completed its acquisition of Antev Limited, a UK-based clinical-stage drug development company. The acquisition was announced on September 2, 2025, and involves a consideration of approximately US$2.97 million in cash and 1,603,164 common shares of Medicus [1].

The acquisition of Antev, which is developing Teverelix, a next-generation GnRH antagonist, adds strategic depth to Medicus' drug development pipeline. Teverelix is a first-in-class market product for acute urinary retention (AURr) and high cardiovascular risk prostate cancer, representing a potential market opportunity of approximately US$6 billion [1].

Following the completion of the acquisition, Patrick J. Mahaffy, a veteran pharma executive and the former chairman of Antev, was appointed to Medicus' board of directors. Dr. Paul Marchetto and Dr. Faisal Mehmud were appointed co-chairmen of Antev's board, while Carolyn Bonner and Viktoria Slepeniuk were also appointed to the board. Amit Kohli will continue to serve as the interim chief executive officer and as a director of Antev [1].

Medicus believes that Teverelix, with its sustained release mechanism and six-week dosing interval, has the potential to become a first-in-class product for preventing acute urinary retention relapse due to enlarged prostate and treating advanced prostate cancer in patients with high cardiovascular risk profiles. The company is currently conducting phase 2b studies for both indications [1].

The acquisition also aligns with Medicus' goal of accelerating the clinical development of disruptive therapeutic assets. The company is actively engaged in multiple countries and has completed a phase 1 study for a novel treatment for basal cell skin cancer [1].

References:
[1] https://www.biospace.com/press-releases/medicus-pharma-ltd-completes-acquisition-of-antev-limited